Dale Biotech ^Company

Dale Biotech develops DBI-500, a small molecule, for the oral treatment of non-alcoholic steatohepatitis (NASH), type 2 diabetes, and COVID-19-related indications. In preclinical models of NASH, T2D, and obesity, we found significant anti-inflammatory and anti-fibrotic effects. These same inflammatory pathways have been shown to be important drivers of disease severity and fibrosis in COVID-19, which may explain the increased risk of severe COVID-19 in these metabolic diseases that are also associated with macrophage activation.